Loading…
← CockpitCompetitor Analysis › 688443.SS Chongqing Genrix Biopharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Chongqing Genrix Biopharmaceutical Co., Ltd. Class A688443.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chongqing biologics developer working on monoclonal antibody drugs including a denosumab-type bone-disease biosimilar.

≈ A small Chinese biologics/biosimilar developerMomentum strong 67
Mkt cap
$1.18B
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$14.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-25.8 pp
WACC 8.1%
Hurdle
n/a
no reverse DCF
Next earnings
168 days
5 May 2027
Close · CNYCN¥23.35
1D-1.7%
1W-10.4%
1M-0.6%
3M-12.7%
6M-22.3%
YTD-14.3%
1Y-21.4%
ATR %5.0%
52w lowhigh28.9% off high

What Chongqing Genrix Biopharmaceutical does

Chongqing biologics developer working on monoclonal antibody drugs including a denosumab-type bone-disease biosimilar.

In one line: A small Chinese biologics/biosimilar developer.

Products and services

  • Bone-disease antibody biologic
  • Other antibody pipeline

Customers

  • Hospitals

Where it sits in the supply chain

  • Pharmaceuticals
  • Biologics
  • Monoclonal antibodies

What could go right

  • Approval and launch of lead biologic

What could go wrong

  • Trial and approval risk
  • Cash burn before commercialization

Moat: none (IP / patents). Early-stage biologics portfolio still dependent on regulatory approval and reimbursement.

Headquarters: Chongqing, China · Employees: 984

Named competitors

Chongqing Genrix Biopharmaceutical at a glance

Size Chongqing Genrix Biopharmaceutical (688443.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.18B, the 1869th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.35 on 18 Nov 2026.

Performance Over six months the shares fell 22.3%, against -11.8% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 255.7% over the last twelve months (peer median -1.5%); the operating margin is -26.9% (peer median 0.8%).

Valuation It trades at 8.6× enterprise value to sales against a peer median of 7.6× (8th most expensive of 18).

Capital Return on invested capital runs 25.8 points below its cost of capital (8.1% WACC).

Next results Next results expected around 5 May 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 86688443.SS 78
Six months, rebased to 100: Chongqing Genrix Biopharmaceutical against the median of its 20 peers (local-currency closes).

Chongqing Genrix Biopharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥801MCN¥230MCN¥29.8MCN¥1.18MCN¥106,041
Revenue growth—+673%+2,435%+1,009%—
Gross profitCN¥690MCN¥149M-CN¥50.1M-CN¥63.3M-CN¥54.0M
EBITDAn/a-CN¥507M-CN¥767M-CN¥731M-CN¥558M
Net income-CN¥209M-CN¥536M-CN¥797M-CN¥801M-CN¥576M
Free cash flow-CN¥296M-CN¥415M-CN¥621M-CN¥469M-CN¥320M
Capital expenditureCN¥105MCN¥85.4MCN¥45.3MCN¥91.0MCN¥146M
Total debtCN¥927MCN¥1.06BCN¥837MCN¥641MCN¥782M

Quarterly statements and history in the cockpit →

Chongqing Genrix Biopharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%NKTR68832168556880620009893000062616HROW3478504547IDIA002550300026AVLNCMHCGPCR000950VIYASH688443.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Chongqing Genrix Biopharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×250×500×750×NKTR68832168556880622616347850300026VIYASH688443.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chongqing Genrix Biopharmaceutical is the large dot.

Chongqing Genrix Biopharmaceutical competitors and peer comparison

Head to head with its named competitors (688443.SS vs AMGN vs 2696.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Chongqing Genrix Biopharmaceutical 688443.SS$1.18B-22%+256%-27%8.6×n/a
Amgen AMGN$240B+34%+9%36%7.2×1.6%
Shanghai Henlius Biotech 2696.HK$3.05B-39%+33%12%3.3×14.1%

How Chongqing Genrix Biopharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chongqing Genrix Biopharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure688443.SSPeer medianRank in peer set
1-month return-0.6%-3.4%9th highest of 21
6-month return-22.3%-11.8%9th lowest of 20
Distance from 52-week high-28.9%-39.3%7th highest of 21
Revenue growth (TTM)+255.7%-1.5%highest of 18
Operating margin-26.9%0.8%7th lowest of 18
EV / Sales8.6×7.6×8th most expensive of 18
ROIC minus cost of capital-25.8 pp-7.5 pp6th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a
Mabwell (Shanghai) Bioscience 688062.SSChina$1.20B-46%+15%-129%13.3×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%2.6×-4.0%-9.0%
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%4.2×3.4%-1.2%
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%8.2×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%1.2×n/an/a
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%2.9×36.3%+20.4%

Questions

Who are Chongqing Genrix Biopharmaceutical's main competitors?
Named competitors: Amgen (AMGN), Henlius Biotech (2696.HK). The cockpit's measured peer set (industry) also includes Nektar Therapeutics (NKTR), Shenzhen Chipscreen Biosciences (688321.SS), Ascentage Pharma Group International (6855.HK), Mabwell (Shanghai) Bioscience (688062.SS), Jiuzhitang (000989.SZ), Chongqing Lummy Pharmaceutical (300006.SZ).
Is Chongqing Genrix Biopharmaceutical expensive compared with its peers?
On ev / sales it trades at 8.6× against a peer median of 7.6×, 8th most expensive of 18 in its peer set.
How has Chongqing Genrix Biopharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -22.3% against -11.8% for the median peer; over one year -21.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.